What to Expect from Pfizer’s Biosimilars Business


Sep. 4 2017, Updated 9:06 a.m. ET

Revenue trends for biosimilars 

In 2Q17, Pfizer’s (PFE) Biosimilars segment reported revenues of ~$121 million, which reflected ~55% growth on a year-over-year (or YoY) basis and 15% growth on a quarter-over-quarter basis. In 1H17, Pfizer’s Biosimilars business reported revenues of ~$226 million compared to $145 million in 1H16. 

The revenue growth for Pfizer’s Biosimilars segment was primarily driven by the increase in sales of Inflectra in the US and Europe.

The chart above represents the revenue curve of Pfizer from 2Q16 to 2Q17. To learn more about Pfizer’s Biosimilars business, please read Pfizer Sees a Significant Opportunity in This for Revenue Growth.

In 2Q17, Pfizer’s Inflectra/Remsima reported revenues of ~$94 million compared to $45 million in 2Q16. In 1H17, Inflectra/Remsima generated revenues of ~$172 million compared to $81 million in 1H16. Inflectra is a biosimilar to Johnson & Johnson’s (JNJ) Remicade (infliximab).

Pfizer markets Nivestim, a biosimilar of filgrastim in certain European, Asian, and Middle East/African countries. Pfizer also commercializes Retacrit (epoetin zeta) in some European, African, and Middle Eastern markets.

In 2Q17, Pfizer’s biosimilars other than inflectra contributed ~$27 million to the company’s revenues compared to $33 million in 2Q16.

Article continues below advertisement

Late-stage studies on biosimilars

Pfizer is conducting various clinical trials for developing biosimilars of blockbuster biologics. Late-stage development is underway with PF-05280014, PF-05280586, PF-06439535, and PF-06410293, which are, respectively, potential biosimilars to Roche’s (RHHBY) Herceptin (trastuzumab), Rituxan (rituximab), Avastin (bevacizumab), and AbbVie’s (ABBV) Humira (adalimumab).

In July 2017, Pfizer filed an application with the European Commission for approval of PF-05280014, a potential biosimilar to Herceptin.

The growth in Pfizer’s Biosimilars segment and simultaneous growth in its revenues could boost the First Trust NASDAQ Pharmaceuticals ETF (FTXH). Pfizer comprises ~8.6% of FTXH’s total portfolio holdings.


More From Market Realist

  • BioNano Genomics Saphyr system
    Company & Industry Overviews
    BioNano Genomics (BNGO) Stock Looks Like a Buy, Solid Opportunity
  • Delta aircraft
    Company & Industry Overviews
    Delta Air Lines Updates Mandatory Vaccine Policy, Explained
  • AMC advertisement in walkway
    Company & Industry Overviews
    Why It's Time for Most Investors to Sell AMC Entertainment Stock
  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.